glp-1 drugs market dynamics 2025 Receptor Agonist Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP-1 Receptor Agonist Market Size
Description
Like Wegovy, each pen delivers a single weekly dose
The significance of these expert insights cannot be overstated
Its prevalence ranges between 5 and 21% 1 , depending on the diagnostic criteria, with higher frequency in women with obesity and specific ethnic groups 2,3
Endogenous GLP-1 has short-lived effects, but pharmaceutical GLP-1 RAs are engineered to have far longer half-lives and therefore sustained physiological impact
However, a significant increase in Bifidobacterium, Dialister , and Alistipes was reported (73)
